A lower trazodone dose of 50-100 mg nightly may be sufficient only in dementia patients with marked slow-wave sleep deficiency

Target: HTR2A; HRH1; AQP4 Composite Score: 0.580 Price: $0.50 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation⚠ Orphaned Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.580
Top 55% of 1402 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.56 Top 67%
C Evidence Strength 15% 0.45 Top 75%
C+ Novelty 12% 0.57 Top 84%
B+ Feasibility 12% 0.74 Top 27%
C+ Impact 12% 0.52 Top 78%
B+ Druggability 10% 0.73 Top 30%
B Safety Profile 8% 0.61 Top 36%
C Competition 6% 0.49 Top 87%
B Data Availability 5% 0.63 Top 48%
C Reproducibility 5% 0.47 Top 78%
Evidence
4 supporting | 3 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

A lower effective dose may exist in a sleep-fragmented subgroup if the beneficial mechanism is indirect, via improved slow-wave sleep rather than direct ISR rescue. This is clinically feasible and testable, but current support is stronger for symptomatic sleep benefit than for true disease modification.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["CSF Arterial Inflow
Periarterial Space"] B["AQP4 on Astrocyte Endfeet
Perivascular Polarization"] C["Glymphatic Flow
ISF Convective Clearance"] D["Abeta/Tau Efflux
Perivenous Drainage"] E["Lymphatic Outflow
Cervical Lymph Nodes"] F["AQP4 Mislocalization
in AD/Aging"] G["Reduced ISF Clearance
Aggregate Accumulation"] A --> B B --> C C --> D D --> E F -.->|"impairs"| C F --> G style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style D fill:#1b5e20,stroke:#81c784,color:#81c784 style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.56 (15%) Evidence 0.45 (15%) Novelty 0.57 (12%) Feasibility 0.74 (12%) Impact 0.52 (12%) Druggability 0.73 (10%) Safety 0.61 (8%) Competition 0.49 (6%) Data Avail. 0.63 (5%) Reproducible 0.47 (5%) KG Connect 0.50 (8%) 0.580 composite
7 citations 7 with PMID Validation: 0% 4 supporting / 3 opposing
For (4)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
4
MECH 3CLIN 4GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Low-dose trazodone improved sleep parameters in pa…SupportingCLIN----PMID:10.1016/j.jagp.2013.12.174-
Acute sleep loss and disruption increase amyloid-b…SupportingCLIN----PMID:32057125-
Additional human work links sleep disruption to AD…SupportingCLIN----PMID:32250301-
Slow-wave sleep loss predicts incident dementia, s…SupportingMECH----PMID:37902739-
Existing trazodone sleep trials in AD were short a…OpposingMECH----PMID:10.1016/j.jagp.2013.12.174-
The glymphatic and sleep-to-neuroprotection bridge…OpposingMECH----PMID:34902819-
Any observed benefit could reflect symptomatic imp…OpposingCLIN----PMID:32057125-
Legacy Card View — expandable citation cards

Supporting Evidence 4

Low-dose trazodone improved sleep parameters in patients with AD, supporting a deployable sleep-architecture m…
Low-dose trazodone improved sleep parameters in patients with AD, supporting a deployable sleep-architecture mechanism.
Acute sleep loss and disruption increase amyloid-beta and tau-related biomarkers in humans.
Additional human work links sleep disruption to AD-related biomarker changes.
Slow-wave sleep loss predicts incident dementia, supporting subgroup enrichment by sleep phenotype.

Opposing Evidence 3

Existing trazodone sleep trials in AD were short and did not demonstrate disease modification.
The glymphatic and sleep-to-neuroprotection bridge remains indirect and partly speculative in humans.
Any observed benefit could reflect symptomatic improvement, reduced agitation, or caregiver-reported function …
Any observed benefit could reflect symptomatic improvement, reduced agitation, or caregiver-reported function rather than slowed neurodegeneration.
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.570.580.59 0.60 0.56 2026-04-252026-04-252026-04-25 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (5)

Paper:10.1016/j.jagp.2013.12.174
No extracted figures yet
Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid.
Annals of neurology (2020) · PMID:32057125
No extracted figures yet
Increased Cerebrospinal Fluid Amyloid-β During Sleep Deprivation in Healthy Middle-Aged Adults Is Not Due to Stress or Circadian Disruption.
Journal of Alzheimer's disease : JAD (2021) · PMID:32250301
No extracted figures yet
Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review.
Sleep medicine reviews (2022) · PMID:34902819
No extracted figures yet
Association Between Slow-Wave Sleep Loss and Incident Dementia.
JAMA neurology (2023) · PMID:37902739
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.630

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
Score: 7.200 | neurodegeneration
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
Score: 7.000 | neurodegeneration
Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation
Score: 6.000 | neurodegeneration
SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration
Score: 5.500 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 HTR2A; — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for HTR2A; structures...
Querying Protein Data Bank API

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)